#non-Hodgkin's lymphoma

CAR-T Therapy: Lifeline to A Cure?

Improved detection methods could make a world of difference for patients undergoing cancer therapy.

A study from the Leukemia & Lymphoma Society finds that antibody production varies widely across blood cancer types.

Zynlonta led to complete remission in nearly a quarter of patients with large B-cell lymphoma.

After a median follow-up of 13 months, four of the five patients had ongoing complete remission.

After approval of the latest cellular therapy for non-Hodgkin lymphoma, the big challenge is how to extend it to common solid tumors.

Half of patients treated with Breyanzi experienced complete remission, and a majority of these responses were durable.

A former labor and delivery nurse, Lindy Sledge, 62, lives with her family in Franklin, Kentucky. She has mantle cell lymphoma.

Yescarta led to complete remission in people with advanced non-Hodgkin lymphoma.

A dedicated student of jiujitsu, Avie Barron, 36, was diagnosed with non-Hodgkin lymphoma in her right lung.

More than a third of people treated with Monjuvi plus Revlimid experienced complete remission.

Tecartus led to durable remission in a majority of participants in a Phase II study.

The popular weed killer has been linked to tens of thousands of cases of non–Hodgkin lymphoma.

The SADAL study showed a 29% response rate for treatment-experienced people with DLBCL.